CA2843417C - Treatment of breast cancer - Google Patents

Treatment of breast cancer Download PDF

Info

Publication number
CA2843417C
CA2843417C CA2843417A CA2843417A CA2843417C CA 2843417 C CA2843417 C CA 2843417C CA 2843417 A CA2843417 A CA 2843417A CA 2843417 A CA2843417 A CA 2843417A CA 2843417 C CA2843417 C CA 2843417C
Authority
CA
Canada
Prior art keywords
alkyl
substituted
compound
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2843417A
Other languages
English (en)
French (fr)
Other versions
CA2843417A1 (en
Inventor
Andrew A. Protter
Jennifer Richer
Dawn Cochrane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Prostate Therapeutics LLC
University of Colorado Colorado Springs
Original Assignee
Medivation Prostate Therapeutics LLC
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2843417(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics LLC, University of Colorado Colorado Springs filed Critical Medivation Prostate Therapeutics LLC
Publication of CA2843417A1 publication Critical patent/CA2843417A1/en
Application granted granted Critical
Publication of CA2843417C publication Critical patent/CA2843417C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2843417A 2011-07-29 2012-07-27 Treatment of breast cancer Active CA2843417C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
US61/513,361 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
CA2843417A1 CA2843417A1 (en) 2013-05-10
CA2843417C true CA2843417C (en) 2018-08-21

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2843417A Active CA2843417C (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Country Status (18)

Country Link
US (4) US9517229B2 (OSRAM)
EP (4) EP3430907A1 (OSRAM)
JP (2) JP6158180B2 (OSRAM)
KR (1) KR101923250B1 (OSRAM)
CN (1) CN103997894B (OSRAM)
BR (1) BR112014002200A2 (OSRAM)
CA (1) CA2843417C (OSRAM)
CY (1) CY1121038T1 (OSRAM)
DK (1) DK2739153T3 (OSRAM)
EA (1) EA028452B1 (OSRAM)
ES (1) ES2696074T3 (OSRAM)
HU (1) HUE040524T2 (OSRAM)
MX (1) MX359664B (OSRAM)
PH (1) PH12014500248B1 (OSRAM)
PL (1) PL2739153T3 (OSRAM)
PT (1) PT2739153T (OSRAM)
SI (1) SI2739153T1 (OSRAM)
WO (1) WO2013066440A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103997894B (zh) * 2011-07-29 2016-08-24 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP6382947B2 (ja) * 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 前立腺癌を治療するためのジヒドロピラジノ−ピラジン化合物及びアンドロゲン受容体アンタゴニストを含む組合せ療法
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP6568093B2 (ja) * 2013-11-07 2019-08-28 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
AU2015360767A1 (en) 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
EA202090103A1 (ru) 2017-06-22 2020-04-24 Селджин Корпорейшн Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
EP3746059A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
MX2020008015A (es) 2018-01-31 2020-10-16 Deciphera Pharmaceuticals Llc Terapia de combinación para el tratamiento de la mastocitosis.
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020113088A1 (en) * 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
JP2023536636A (ja) * 2020-08-03 2023-08-28 オンコサイト・コーポレイション 腫瘍の分類及び応答性の予測
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR102481886B1 (ko) * 2005-05-13 2022-12-28 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
LT2656842T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
CN102755318B (zh) * 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
PE20121470A1 (es) * 2007-10-26 2012-11-18 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) * 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
HRP20140140T1 (en) 2008-05-30 2014-05-23 The University Of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
BRPI1007990A2 (pt) 2009-02-24 2015-09-01 Medivation Prostate Therapeutics Inc Compostos específicos de diaril-hidantoína e diariltioidantoína.
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
WO2012125828A2 (en) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methods of treating breast cancer with anthracycline therapy
CN103997894B (zh) * 2011-07-29 2016-08-24 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗
CA2857505A1 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
CA2882621A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
AU2015360767A1 (en) 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
EP2739153A1 (en) 2014-06-11
MX359664B (es) 2018-10-05
CN103997894B (zh) 2016-08-24
PL2739153T3 (pl) 2019-04-30
HUE040524T2 (hu) 2019-03-28
EP3430907A1 (en) 2019-01-23
ES2696074T3 (es) 2019-01-14
WO2013066440A1 (en) 2013-05-10
SI2739153T1 (sl) 2018-12-31
US20210069154A1 (en) 2021-03-11
PT2739153T (pt) 2018-11-28
JP6158180B2 (ja) 2017-07-05
JP2014524934A (ja) 2014-09-25
EP3791724A1 (en) 2021-03-17
KR101923250B1 (ko) 2018-11-28
PH12014500248A1 (en) 2014-03-17
US20170087132A1 (en) 2017-03-30
JP2017141269A (ja) 2017-08-17
PH12014500248B1 (en) 2018-08-31
MX2014001218A (es) 2014-08-22
US9517229B2 (en) 2016-12-13
HK1198867A1 (en) 2015-06-19
EP2739153B1 (en) 2018-08-22
CA2843417A1 (en) 2013-05-10
CY1121038T1 (el) 2019-12-11
US20140296312A1 (en) 2014-10-02
BR112014002200A2 (pt) 2017-03-07
US10111861B2 (en) 2018-10-30
US20190262315A1 (en) 2019-08-29
EP3610731A1 (en) 2020-02-19
EA201400178A1 (ru) 2014-11-28
CN103997894A (zh) 2014-08-20
DK2739153T3 (en) 2018-12-03
EA028452B1 (ru) 2017-11-30
KR20140107174A (ko) 2014-09-04
HK1201413A1 (en) 2015-09-04
EP2739153A4 (en) 2015-03-11
WO2013066440A9 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
CA2843417C (en) Treatment of breast cancer
JP6027662B2 (ja) 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤
RS66727B1 (sr) Kombinacija dasatiniba i adagrasiba za primenu u lečenju nesitnoćelijskog kancera pluća
AU2015288381B2 (en) Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer
EP3120849A1 (en) Cancer stem cell proliferation inhibitor and intracellular active oxygen accumulation inducer
WO2013067151A1 (en) Treatment methods using diarylthiohydantoin derivatives
US20120053559A1 (en) Treatment of Proliferative Diseases with Epothilone Derivatives and Radiation
CN103619331A (zh) 抗癌治疗剂
HK1201413B (en) Treatment of breast cancer
CN108299390A (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
AU2014290012B2 (en) Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
HK1198867B (en) Treatment of breast cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170720